Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD D KIM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1609810779
CMS profile
344689
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$154,676.84

165 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $50,871.38 39
Incyte Corporation $41,265.77 46
ABBVIE INC. $15,942.11 8
Genentech USA, Inc. $9,523.14 8
Eisai Inc. $9,413.86 11
Pharmacosmos Therapeutics Inc. $5,178.60 11
PFIZER INC. $4,882.91 9
ARRAY BIOPHARMA INC $4,843.58 8
GlaxoSmithKline, LLC. $4,000.00 1
Exelixis Inc. $2,808.54 6
TAIHO ONCOLOGY, INC. $1,707.43 2
Bayer Healthcare Pharmaceuticals Inc. $1,635.21 2
SANOFI-AVENTIS U.S. LLC $1,568.00 1
Ipsen Biopharmaceuticals, Inc $460.25 5
Seagen Inc. $167.28 3
Medtronic, Inc. $166.67 1
AngioDynamics, Inc. $74.62 1
Foundation Medicine, Inc. $71.82 1
Merck Sharp & Dohme LLC $59.00 1
SERVIER PHARMACEUTICALS LLC $36.67 1

Page 4 of 4; records 151–165 of 165 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD D KIM

NPI 1609810779 · CMS profile ID 344689

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–165 of 165 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609810779?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD D KIM, NPI 1609810779, CMS profile ID 344689. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–165 of 165 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609810779?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RICHARD D KIM, NPI 1609810779, CMS profile ID 344689. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–165 of 165 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609810779?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RICHARD D KIM, NPI 1609810779, CMS profile ID 344689, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–165 of 165 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1609810779?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

165 matching records · $154,676.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 165 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–165 of 165.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $680.0001/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023329251 CMS
Eisai Inc. $1,700.0001/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023329259 CMS
Eisai Inc. $122.1601/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023329261 CMS
Seagen Inc. $44.6501/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995788973 CMS
AstraZeneca Pharmaceuticals LP $134.7001/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014992831 CMS
SERVIER PHARMACEUTICALS LLC $36.6701/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055093069 CMS
Ipsen Biopharmaceuticals, Inc $23.4601/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405103 CMS
PFIZER INC. $490.3501/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050516713 CMS
TAIHO ONCOLOGY, INC. $57.4301/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055233455 CMS
PFIZER INC. $204.4901/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050542719 CMS
PFIZER INC. $3,275.0001/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050555153 CMS
PFIZER INC. $239.0601/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050626539 CMS
PFIZER INC. $92.4501/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049485719 CMS
PFIZER INC. $432.3601/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050533539 CMS
Bayer Healthcare Pharmaceuticals Inc. $1,521.9001/05/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000788536 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $50,630.05 59
PY2020 $38,911.38 36
PY2021 $148,365.14 131
PY2022 $108,494.80 132
PY2023 $154,676.84 165
PY2024 $90,121.82 90
PY2025 $46,073.13 79

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $296.25 3
PY2025 Principal investigator $426,132.69 26
PY2024 Principal investigator $96,757.22 12
PY2023 Principal investigator $170,821.04 26
PY2022 Principal investigator $1,438,664.20 113
PY2021 Principal investigator $1,399,785.70 113
PY2020 Recipient $3,100.00 1
PY2020 Principal investigator $1,748,117.92 157
PY2019 Principal investigator $2,578,383.07 163

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $974.00 11/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712582
Principal investigator 1 PFIZER INC. $87,175.19 11/19/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712584
Principal investigator 1 PFIZER INC. $974.00 11/10/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712586
Principal investigator 1 PFIZER INC. $252.00 10/20/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228712786
Principal investigator 1 PFIZER INC. $822.00 09/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228748599
Principal investigator 1 PFIZER INC. $3,305.34 09/29/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228758320
Principal investigator 1 AstraZeneca UK Limited $712.00 09/23/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma No dispute reported 06/30/2026 1185543136
Principal investigator 1 PFIZER INC. $22,938.03 09/15/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228759218
Principal investigator 1 PFIZER INC. $23,446.13 09/08/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228753801
Principal investigator 1 PFIZER INC. $822.00 08/25/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228770194
Principal investigator 1 AstraZeneca Pharmaceuticals LP $96,611.00 08/07/2025 Covered Recipient Teaching Hospital
Moffitt Cancer Center
A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma No dispute reported 06/30/2026 1185543134
Principal investigator 1 PFIZER INC. $3,312.00 08/04/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228786273
Principal investigator 1 PFIZER INC. $9,262.14 07/28/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228766098
Recipient SERVIER PHARMACEUTICALS LLC $98.25 07/24/2025 Covered Recipient Physician A Phase 1b multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer No dispute reported 06/30/2026 1235964826
Recipient SERVIER PHARMACEUTICALS LLC $99.75 07/24/2025 Covered Recipient Physician A Phase 1b multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer No dispute reported 06/30/2026 1235964828
Principal investigator 1 PFIZER INC. $642.00 07/21/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228764002
Principal investigator 1 PFIZER INC. $1,424.00 06/02/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228722456
Principal investigator 1 PFIZER INC. $16,836.80 06/02/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228793054
Principal investigator 1 PFIZER INC. $67,798.72 05/05/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228772590
Principal investigator 1 PFIZER INC. $23,446.13 04/28/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228780080
Principal investigator 1 PFIZER INC. $8,930.30 04/07/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228778686
Principal investigator 1 PFIZER INC. $204.00 03/31/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228796128
Recipient SERVIER PHARMACEUTICALS LLC $98.25 03/19/2025 Covered Recipient Physician A Phase 1b multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer No dispute reported 06/30/2026 1235964824
Principal investigator 1 PFIZER INC. $22,793.60 03/03/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228795912
Principal investigator 1 PFIZER INC. $266.00 03/03/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228796192
Principal investigator 1 PFIZER INC. $470.00 02/18/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228793833
Principal investigator 1 PFIZER INC. $204.00 02/18/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228794736
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,204.00 02/11/2025 Non-covered Recipient Entity
H Lee Moffit Cancer Center And Research Institute
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma after Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 1235997025
Principal investigator 1 PFIZER INC. $28,307.31 02/03/2025 Covered Recipient Teaching Hospital
MOFFITT CANCER CENTER
A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228797613